Core Insights - Nordberg Medical and Giant Bio have signed a strategic cooperation agreement to jointly advance the global development and commercialization of recombinant collagen in the medical aesthetics and biomedical fields [1][2] Group 1: Strategic Cooperation - The agreement grants Nordberg Medical the rights to develop, produce, and commercialize Giant Bio's patented recombinant collagen in global markets outside mainland China [1] - This collaboration aims to enhance Nordberg Medical's position in the rapidly growing anti-aging regenerative solutions sector [1][2] Group 2: Market Potential - The injectable medical aesthetics market is projected to reach $10 billion by 2026, highlighting significant growth opportunities for Nordberg Medical [2] - The partnership is expected to diversify the product portfolio and strengthen innovation capabilities in regenerative medicine [2] Group 3: Company Background - Nordberg Medical is a Swedish biotechnology and medical device company focused on creating innovative biomedical solutions that connect nature and science [3] - The flagship brand, JULÄINE of Sweden™, features a new generation of collagen biostimulants that activate the body's natural collagen regeneration [3] - The company has received regulatory approvals for its products in 33 markets and is expanding its direct sales network across over 20 countries, with plans to enter North America, South America, and the Middle East [4]
巨子生物携手瑞典Nordberg Medical，迈向「生态出海」新阶段